ELISAs to Quantify Cytokine Release
At Biomedica we develop and manufacture quality ELISAs to quantify cytokine release
Our ELISAs to quantify cytokine release are validated according to international quality guidelines to ensure their consistency, specificity, precision, and robustness. The validation data files can be found on the respective product pages www.bmgrp.com.
Our kits are designed to specifically quantify cytokine release in various biological matrices (e.g. serum, plasma, cell culture).
WHO reference reagents for a harmonized standardization
All our cytokine kits are standardized using WHO reference reagents/standards to allow cross-comparison of results when using different reagent sets during a study (1).
BIOMEDICAs CYTOKINE ELISA KITS
IL-6 ELISA (cat. no. BI-IL6)
The Biomedica IL-6 (interleukin-6) ELISA kit is a sandwich ELISA that incorporates two epitope-mapped antibodies that specifically bind to human IL-6 in the respective samples.
Capture antibody (pre-coated on a 96-well microtiter plate): recombinant IL-6 antibody (specific for human IL-6).
Detection antibody: polyclonal IL-6 antibody (streptavidin-HRPO labeled), specific for human IL-6.
-
- Method: sandwich ELISA
- Sample type: serum, plasma, cell-culture, urine
- Sample volume: 100µl / well
- Assay time: 4.5 hrs
- Standard range: 0 / 3.1 – 200 pg/ml
- Sensitivity: LOD: 0.28 pg/ml; LLOQ: 0.78 pg/ml (measurable concentrations in serum AND plasma samples!)
- Precision: in-between-run (n=9 ): ≤ 6 % CV, within-run (n=3): ≤ 7 % CV
- Specificity: the ELISA recognizes recombinant and endogenous (natural) human IL-6
- Standard matrix: serum based matrix containing recombinant IL-6 including 8x vials of pre-diluted standards, lyophilized
- Controls: 2 controls (high and low) included
VEGF ELISA (cat. no. BI-VEGF)
The Biomedica VEGF (Vascular Endothelial Growth Factor) ELISA kit is a sandwich ELISA that incorporates two epitope-mapped antibodies that specifically bind to human VEGF in the respective samples.
Capture antibody (pre-coated on a 96-well microtiter plate): recombinant VEGF antibody (specific for human VEGF) recognizes a structural epitope in the conserved receptor binding- site of the VEGF peptide. The antibody binds to all VEGF isoforms.
Detection antibody: polyclonal VEGF antibody (streptavidin-HRPO labeled), specific for human VEGF, recognizing multiple linear epitopes that are concentrated in the first 120 amino acids in the N-terminal region of the VEGF molecule.
- Method: sandwich ELISA
- Sample type: serum, plasma, cell-culture, urine
- Sample volume: 10µl / well
- Assay time: 4.5 hrs
- Standard range: 0 / 31.2 – 2000 pg/ml
- Sensitivity: LOD: 2.5 pg/ml; LLOQ: 15.6 pg/ml (measurable concentrations in serum AND plasma samples)
- Precision: in-between-run: (n=3): ≤ 6 % CV, Within-run (n=3): ≤ 3 % CV
- Specificity: the ELISA recognizes recombinant and endogenous (natural) human VEGF including all circulating VEGF isoforms including VEGF165b
- Standard matrix: Serum based matrix containing recombinant VEGF, including 8x vials of pre-diluted standards, lyophilized
- Controls: 2 controls (high and low) included
ANGIOPOIETIN-2 ELISA (cat. no. BI-ANG2)
The Biomedica ANG2 (Angiopoietin-2) ELISA kit is a sandwich ELISA that incorporates two epitope-mapped antibodies that specifically bind to human Angiopoietin-2 in the respective samples.
Capture antibody (pre-coated on a 96-well microtiter plate): recombinant ANG2 antibody (specific for human ANG2).The capture antibody has a structural epitope that binds to the receptor binding site of human Angiopoietin-2. The receptor binds to TEL / TIE2 protein.
Detection antibody: polyclonal ANG2 antibody (streptavidin-HRPO labeled), specific for human ANG2, recognizing several linear epitopes that are distributed over the entire Angiopoietin-2 molecule.
- Method: sandwich ELISA
- Sample type: serum, plasma, cell-culture, urine
- Sample volume: 20µl / well
- Assay time: 3.5 hrs
- Standard range: 0 / 12.5 – 400 pg/ml
- Sensitivity: 3.7 pmol/l (= 203 pg/ml)
- Precision: In-between-run (n=9): ≤ 6 % CV, Within-run (n=3): ≤ 8 % CV
- Specificity: the ELISA recognizes recombinant and endogenous (natural) human ANG2. The assay most probably detects all three ANG2 isoforms, as determined by epitope mapping and analysis of the ANG2 sequence. ANG1 is not detected in this ELISA assay.
- Standard matrix: Serum based matrix containing recombinant ANG2, including 8x vials of pre-diluted standards, lyophilized
- Controls: 2 controls (high and low) included
Also available: Mouse /rat Angiopoietin-2 ELISA (cat. no. BI-ANG2MR)
Related publications
1. International reference reagents
2. Targeting IL-6 trans-signalling: past, present and future prospects. Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J. Nat Rev Immunol. 2023 Apr 17:1–16. doi: 10.1038/s41577-023-00856-y. Epub ahead of print. PMID: 37069261; PMCID: PMC10108826.
Abstract
Interleukin-6 (IL-6) is a key immunomodulatory cytokine that affects the pathogenesis of diverse diseases, including autoimmune diseases, chronic inflammatory conditions and cancer. Classical IL-6 signalling involves the binding of IL-6 to the membrane-bound IL-6 receptor α-subunit (hereafter termed ‘mIL-6R’) and glycoprotein 130 (gp130) signal-transducing subunit. By contrast, in IL-6 trans-signalling, complexes of IL-6 and the soluble form of IL-6 receptor (sIL-6R) signal via membrane-bound gp130. A third mode of IL-6 signalling – known as cluster signalling – involves preformed complexes of membrane-bound IL-6-mIL-6R on one cell activating gp130 subunits on target cells. Antibodies and small molecules have been developed that block all three forms of IL-6 signalling, but in the past decade, IL-6 trans-signalling has emerged as the predominant pathway by which IL-6 promotes disease pathogenesis. The first selective inhibitor of IL-6 trans-signalling, sgp130, has shown therapeutic potential in various preclinical models of disease and olamkicept, a sgp130Fc variant, had promising results in phase II clinical studies for inflammatory bowel disease. Technological developments have already led to next-generation sgp130 variants with increased affinity and selectivity towards IL-6 trans-signalling, along with indirect strategies to block IL-6 trans-signalling. Here, we summarize our current understanding of the biological outcomes of IL-6-mediated signalling and the potential for targeting this pathway in the clinic.